Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

FP5

ANTICANCER RETINOIDS Résumé de rapport

Project ID: QLK3-CT-2002-02029
Financé au titre de: FP5-LIFE QUALITY
Pays: Spain

Panel of family and isotype selective retinoid modulators (agonists, partial agonists, inverse agonists, antagonists)

Known and potent, as well as novel RAR and RXR modulators (agonists, antagonists, inverse agonists&) for use in the research carried out by the Consortium members were prepared.

These benchmark retinoids are important biological tools for research.
Among the compounds prepared through ligand design and synthesis, two are particularly noteworthy:
- UVI3003, a powerful and selective RXR antagonist.
- UVI2034, a selective RAR-antagonist
Compound UVI3003 has been used in the context of RXR signalling pathways, as well as in the context of structural-activity determination.

In addition, compound UVI2003 has served as a derivative of TTNPB to show the role of the halogen at the benzoic acid end in the RARß ligand discrimination.

Contact

Angel DE LERA, (Professor)
Tél.: +34-986812316
Fax: +34-986811940
E-mail